In addition, some of these CCRGs have been used as antitumor targets or suggested to be related to therapeutic resistance in BC; however, some of them, including CCNB2, CDC20, PTTG1 and BUB1B, have not yet been determined as antitumor targets or to be related to therapeutic resistance in BC. This evidence concerns the gene BUB1B and breast cancer.